Search

Your search keyword '"Glass, Bertram"' showing total 12 results
Start Over Author "Glass, Bertram" Journal annals of hematology
12 results on '"Glass, Bertram"'

2. Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)

Author

Zettl, Florian, Ziepert, Marita, Altmann, Bettina, Zeynalova, Samira, Held, Gerhard, Pöschel, Viola, Hohloch, Karin, Wulf, Gerald G., Glass, Bertram, Schmitz, Norbert, Loeffler, Markus, and Trümper, Lorenz

Published
2021
Full Text
View/download PDF

3. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT

Author

Schmidt-Hieber, Martin, Tridello, Gloria, Ljungman, Per, Mikulska, Malgorzata, Knelange, Nina, Blaise, Didier, Socié, Gerard, Volin, Liisa, Blijlevens, Nicole, Fegueux, Nathalie, Yakoub-Agha, Ibrahim, Forcade, Edouard, Maertens, Johan, Chevallier, Patrice, Passweg, Jakob, Cornelissen, Jan, Russell, Nigel, Craddock, Charles, Bourhis, Jean Henri, Marchand, Tony, Reményi, Péter, Cahn, Jean Yves, Michallet, Mauricette, Montoto, Silvia, Kröger, Nicolaus, Glaß, Bertram, and Styczynski, Jan

Published
2019
Full Text
View/download PDF

7. Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)

Author

Zettl, Florian, primary, Ziepert, Marita, additional, Altmann, Bettina, additional, Zeynalova, Samira, additional, Held, Gerhard, additional, Pöschel, Viola, additional, Hohloch, Karin, additional, Wulf, Gerald G., additional, Glass, Bertram, additional, Schmitz, Norbert, additional, Loeffler, Markus, additional, and Trümper, Lorenz, additional

Published
2020
Full Text
View/download PDF

12. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-anti-CD20 antibody and stem cell rescue.

Author

Hohloch, Karin, Sahlmann, Carsten, Lakhani, Vijai, Wulf, Gerald, Glaß, Bertram, Hasenkamp, Justin, Meller, Johannes, Riggert, Joachim, Trümper, Lorenz, and Griesinger, Frank

Subjects
STEM cell transplantation research, RADIOIMMUNOTHERAPY, RITUXIMAB, B cells, DISEASE progression, LYMPHOMAS, SALVAGE therapy, PNEUMONIA
Abstract

A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-anti-CD20 antibody (I-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed ( n = 14) and refractory ( n = 2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 ( n = 4), transformed follicular (FL 3b; n = 6), diffuse large B-cell (DLBCL; n = 4), mantle cell ( n = 1) and marginal zone lymphoma ( n = 1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results